Please use this identifier to cite or link to this item:
https://doi.org/10.3390/brainsci10020122
DC Field | Value | |
---|---|---|
dc.title | Enhancing ?-secretase processing for Alzheimer’s disease—a view on SFRP1 | |
dc.contributor.author | Tang, B.L. | |
dc.date.accessioned | 2021-08-10T03:05:13Z | |
dc.date.available | 2021-08-10T03:05:13Z | |
dc.date.issued | 2020 | |
dc.identifier.citation | Tang, B.L. (2020). Enhancing ?-secretase processing for Alzheimer’s disease—a view on SFRP1. Brain Sciences 10 (2) : 122. ScholarBank@NUS Repository. https://doi.org/10.3390/brainsci10020122 | |
dc.identifier.issn | 2076-3425 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/196209 | |
dc.description.abstract | Amyloid ? (A?) peptides generated via sequential ?-and ?-secretase processing of the amyloid precursor protein (APP) are major etiopathological agents of Alzheimer’s disease (AD). However, an initial APP cleavage by an ?-secretase, such as the a disintegrin and metalloproteinase domain-containing protein ADAM10, precludes ?-secretase cleavage and leads to APP processing that does not produce A?. The latter appears to underlie the disease symptom-attenuating effects of a multitude of experimental therapeutics in AD animal models. Recent work has indicated that an endogenous inhibitor of ADAM10, secreted-frizzled-related protein 1 (SFRP1), is elevated in human AD brains and associated with amyloid plaques in mouse AD models. Importantly, genetic or functional attenuation of SFRP1 lowered A? accumulation and improved AD-related histopathological and neurological traits. Given SFRP1?s well-known activity in attenuating Wnt signaling, which is also commonly impaired in AD, SFRP1 appears to be a promising therapeutic target for AD. This idea, however, needs to be addressed with care because of cancer enhancement potentials resulting from a systemic loss of SFRP1 activity, as well as an upregulation of ADAM10 activity. In this focused review, I shall discuss ?-secretase-effected APP processing in AD with a focus on SFRP1, and explore the contrasting perspectives arising from the recent findings. © 2020 by the author. Licensee MDPI, Basel, Switzerland. | |
dc.publisher | MDPI AG | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Scopus OA2020 | |
dc.subject | ADAM10 | |
dc.subject | Alzheimer’s disease | |
dc.subject | Amyloid ? (A?) | |
dc.subject | Secreted-frizzled-related protein 1 (SFRP1) | |
dc.type | Review | |
dc.contributor.department | BIOCHEMISTRY | |
dc.description.doi | 10.3390/brainsci10020122 | |
dc.description.sourcetitle | Brain Sciences | |
dc.description.volume | 10 | |
dc.description.issue | 2 | |
dc.description.page | 122 | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_3390_brainsci10020122.pdf | 637.03 kB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License